Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors

Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Riikka Havunen, Joao M. Santos, Emma Kutvonen, James H.A. Clubb, Mikko Siurala, Camilla Heiniö, Sadia Zafar, Teija Koivula, Dave Lumen, Marjo Vaha, Arturo Garcia-Horsman, Anu J. Airaksinen, Suvi Sorsa, Marjukka Anttila, Veijo Hukkanen, Anna Kanerva, Akseli Hemminki

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Abstrakti

Despite some promising results, the majority of patients do not benefit from T-cell therapies, as tumors prevent T-cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcome many of the barriers currently facing T-cell therapies of solid tumors. This study aims to understand how four different oncolytic viruses (adenovirus, vaccinia virus, herpes simplex virus and reovirus) perform in that task. For that purpose, an immunocompetent in vivo tumor model featuring adoptive tumor-infiltrating lymphocyte (TIL) therapy was used. Tumor growth control (p
Alkuperäiskielienglanti
LehtiMolecular Therapy - Oncolytics
ISSN2372-7705
DOI - pysyväislinkit
TilaJulkaistu - 19 maaliskuuta 2020
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3122 Syöpätaudit

Siteeraa tätä